instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
Biotechnology company Alkermes said earlier in the day that it expected Lilly to drop out of their program to develop an inhaled insulin treatment for diabetes, sending Alkermes shares down more than 9 percent. Lilly's decision marks the third setback in recent months for inhaled insulin formulations, once deemed potential blockbuster products because of their greater convenience than standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the alcohol addiction drug Vivitrol, said Lilly has the right to terminate its license to the inhaled treatment, Air Insulin, at its discretion. "While Lilly may elect not to commercialize Air Insulin, Alkermes believes that the phase 3 safety and efficacy trials should be completed," Alkermes said in a statement. After Lilly's announcement, the company said it was evaluating the impact of the termination, which will become effective in 90 days. Indianapolis-based Lilly said its decision was not due to safety concerns, "but rather was a result of increasing uncertainties in the regulatory environment, and a thorough evaluation of the evolving commercial and clinical potential of the product compared to existing medical therapies." Lilly Chief Operating Officer John Lechleiter said in a statement that the company is beginning the process of halting ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of around $90 million to $120 million, or 5 cents to 7 cents per share. The company said its adjusted earnings per share outlook remains unchanged at $3.85 to $4.00, while net earnings will range from $3.73 to $3.90. Lilly's action comes just five months after Pfizer Inc abandoned Exubera, the first approved inhaled form of insulin, and returned rights to the product to longtime partner Nektar Therapeutics. Exubera had dismal sales because patients were turned off by the clumsy device used to administer the powdered insulin and because doctors were concerned by the drug's tendency to slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with Reuters in October, said Air Insulin may have similar effects on lung function. "We're assuming that pulmonary insulins in that regard are all pretty much the same," he said, although a conclusive picture of Air Insulin's safety will not emerge until two-year safety trials of the product end later this year. A second setback for inhaled insulin came in January, when Novo Nordisk said it was halting development of its AERx product, meant to deliver inhaled droplets. The Danish drugmaker said AERx did not have adequate sales potential, given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly's abandonment of AIR Insulin made good business sense. "We are not (at) all surprised, and have never been strong advocates of the pulmonary insulin agents, following the poor launch and ultimate demise of Pfizer and Nektar's Exubera and Novo Nordisk's termination of its AERx program," Rubin said in a research note. Rubin said Alkermes, known for its drug-delivery technology, is unlikely to continue development of Air Insulin without Lilly, "given that this represents the third termination of a pulmonary insulin drug." But she said the sharp drop in Alkermes shares represented a buying opportunity for investors because Air Insulin had only paltry sales potential. She said investors should be focused instead on another product Alkermes is developing with Lilly: a long-acting formulation of Lilly's Byetta diabetes treatment called Byetta "We estimate that Byetta LAR could be worth $11 to $12 for the (Alkermes) stock," Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling products, rose 2 cents to end at $49.70 on the New York Stock Exchange, and was slightly lower at $49.67 in after-hours trading.
answer:
Eli Lilly drops inhaled insulin program.

question:
The news release does not mention costs. While a new therapy may not have an established price, the release could have stated "no price is available for this drug." What would be even better is some context for what women suffering from postpartum pay typically for counseling and medications. The release notes that there was a reduction in depressive symptoms of 17 points for those on the drug, and 12.8 for those in the placebo group based on the Hamilton Depression Rating Scale. The absolute reduction in the rating scale is given for each group. This information would have been much more helpful if the release also clarified the magnitude of the scale and whether a 4.2-point difference is clinically meaningful. The release contains one somewhat vague sentence on harms. The most common (10% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence. Readers would also be interested in details on whether the drug is safe for nursing infants. That's not mentioned. The double-blinded randomized trials are described in detail and readers are able to judge the quality of the evidence. The published study includes an important limitation of the research that's not mentioned in the release: The trials assessed women for only 30 days; the effects of the treatment beyond 30 days are "unknown." There is no disease mongering. The release explains how common postpartum depression is worldwide. The release notes that Sage Therapeutics funded the research. Sage Therapeutics is the developer of brexanolone injection and sponsor of the trials. A New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation. The FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018. What the release doesn't tell us is that both quoted researchers disclosed financial ties with Sage Therapeutics. This information was included in the studies published in the Lancet. SM-B reports personal fees from MedScape and grants from Sage Therapeutics, awarded to the University of North Carolina DRR reports personal fees and has stock options in Sage Therapeutics. The release mentions that women currently can receive antidepressants for postpartum depression, but that the new drug being studied goes to work relieving symptoms faster than traditional antidepressants days rather than weeks. The release notes that the drug is currently under FDA review, with a decision on its approval expected by the end of the year. The release notes that the new drug would be a novel treatment for postpartum depression, if approved. There is no unjustifiable language.
answer:
Newly Published Results Show Investigational Treatment Brexanolone Consistently Reduced Depressive Symptoms Across Three Postpartum Depression Trials, Supporting Submission for FDA Approval

question:
Lexicon shares, which have lost about 15 percent of their value last year, fell as much as 7.5 percent to $1.85 on the Nasdaq in early trading on Monday. The company said Arthur Sands, CEO since 1995 and a co-founder, intends to develop a succession plan with the board. He will continue in his position until a successor is appointed. Analysts said Sands might have been perceived as more of a scientist who would not be able to lead the company into a commercial launch of the late-stage drugs. "I think Arthur Sands could have easily done the transition to commercial, but possibly the board felt they wanted someone with direct commercial experience", Wedbush analyst Liana Moussatos said. Lexicon said it would cut 115 jobs, primarily positions in research and discovery, to reduce costs. The company said it would focus mainly on its drugs to treat diabetes and carcinoid syndrome, a condition which affects some people with a rare cancerous tumor. "Most of the value of the company is wrapped up in these late-stage drugs," Morningstar analyst Karen Andersen said. "It makes sense to focus on what investors are really looking at." Lexicon said it expects to lower expenses by about $14 million, net of severance costs and some other charges, for the rest of 2014. It expects to save about $22 million annually. "This could give them an extra two to three quarters of cash," Moussatos said. The company had $151.2 million in cash and investments as of September 30 last year. Andersen said Lexicon needed to conserve cash while it looked for a partner to fund the development of its diabetes drug. "In order to do a comprehensive diabetes program, it takes hundreds of millions of dollars, which is more than Lexicon can afford right now," she said. The company is testing two other drugs in mid-stage trials to treat irritable bowel syndrome and rheumatoid arthritis. It also has a glaucoma drug in early-stage development. Moussatos said that Lexicon could license the development of the drugs to other pharmaceutical companies. Lexicon has drug discovery agreements with Bristol-Myers Squibb Co, Roche Holding AG's unit Genentech and Takeda Pharmaceutical Co Ltd. Lexicon shares, which once traded above $40, were down 4.5 percent at $1.91.
answer:
Lexicon Pharma to cut 45 percent of workforce, CEO to leave.